To view the full article click here.
Proactive Investors: Michael Hunt updates on product development
Proactive Investors: ‘Lots to look forward to’ as ReNeuron gets go-ahead for phase IIb stroke trial
Michael Hunt, CFO of ReNeuron Group Plc (LON:RENE), tells Proactive they’ve been given the green light from US authorities to kick off a phase IIb study of its CTX cell therapy candidate for stroke disability.
Long-term data from the PISCES II trial earlier this year showed the treatment has the potential to improve the disability of stroke patients.
PISCES III – as this next study will be called – will be much bigger, recruiting 110 patients across 25 sites in the US.
The approval caps off a productive six months for the cell-based therapeutics specialist, during which it also started dosing patients in the phase II element of the ongoing phase I/II clinical trial of its hRPC stem cell therapy candidate for retinitis pigmentosa
Proactive Investors: Michael Hunt discusses very encouraging long-term stroke data
To view the full article click here…
Proactive Investors: ReNeuron gears up for Phase III stroke disability study
To view the full article click here…
Proactive Investors: ReNeuron ‘greatly encouraged’ by US regulator feedback on CTX cell therapy trial
To view the full article click here…
Proactive Investors: CFO discusses very significant exosome therapy data
To view the full article please click here…
Proactive Investors : CFO ‘very pleased’ to be awarded £1.8m grant
To view the full article click here…
Proactive Investors : CFO ‘pleased’ with reformulation of degenerative diseases treatment
To view the full article click here…
ReNeuron featured in BBC documentary “Andrew Marr: My Brain and Me”
ReNeuron’s CTX cell therapy candidate has been featured in the BBC documentary, “Andrew Marr: My Brain and Me”, which was screened for the first time on 14 February 2017 on BBC2.
Click on the image above to watch on the the BBC iPlayer.
CEO Olav Hellebo interview on CNBC
